SEC Comment Letter for Histogen Inc. (CIK 0001383701) — Dec 28, 2020
Histogen Inc. (CIK 0001383701)
Date: Dec. 28, 2020 · CIK: 0001383701 · Accession: 0000000000-20-012432
AI Filing Summary & Sentiment
File numbers found in text: 333-251491
Letter
United States securities and exchange commission logo December 28, 2020 Richard Pascoe Chief Executive Officer Histogen Inc. 10655 Sorrento Valley Road, Suite 200 San Diego, CA 92121 Re:Histogen Inc. Registration Statement on Form S-1 Filed December 18, 2020 File No. 333-251491 Dear Mr. Pascoe: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason L. Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Larry Nishnick, Esq.
Show Raw Text
United States securities and exchange commission logo
December 28, 2020
Richard Pascoe
Chief Executive Officer
Histogen Inc.
10655 Sorrento Valley Road, Suite 200
San Diego, CA 92121
Re:Histogen Inc.
Registration Statement on Form S-1
Filed December 18, 2020
File No. 333-251491
Dear Mr. Pascoe:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason L. Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Larry Nishnick, Esq.